Nuvectis Pharma taps public markets to fund cancer and immune drug pipeline
What's the deal? Nuvectis Pharma (Nasdaq: NVCT), a clinical-stage biopharmaceutical company in Fort Lee, New Jersey, has launched an underwritten public offering of its common stock.
The company will sell all the shares itself and plans to grant underwriters a 30-day option to buy up to an additional 15%. Cantor FitzgeraldDealroom has a profile for this one. Try Dealroom → is acting as sole book runner.
Proceeds will advance three drug candidates — NXP100, NXP200, and NXP900 — alongside hiring, capital spending, and general corporate costs.
Why now? Nuvectis filed its shelf registration with the U.S. Securities and Exchange Commission (SEC) in February 2026, clearing the way to raise capital quickly when market conditions allow.
The pipeline is moving toward later stages. NXP100, a once-daily oral Factor B inhibitor, targets complement-mediated diseases that require lifelong treatment.
What could go wrong? The offering hinges on market conditions, and the company says there is no assurance it will close — or at what size or terms.
The candidates remain in development. NXP900 inhibits the SRC family of kinases, while NXP200 is a brain-penetrant BRAF inhibitor aimed at solid tumours, including melanoma and lung cancer.
The signal: Clinical-stage biotechs lean on equity markets to bankroll long, costly trials, and shelf registrations let them move fast when windows open. With Cantor FitzgeraldDealroom has a profile for this one. Try Dealroom → steering the offering as sole book runner, Nuvectis is betting that investors will fund its push toward best-in-class oncology and immune therapies before any product reaches the market.
Read more: MarketScreener
Image credit: History at NIH
